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Human enterovirus 71 (EV71) is an important human enterovirus which belongs 
to the Enterovirus genus of the Picornaviridae family. Large outbreaks of EV71 
have been associated with severe central nervous disease (CNS) manifestations 
including the hand, foot and mouth disease (HFMD). To date, there is no 
effective antiviral drug available to treat the infections. Therefore, the 
development of an effective vaccine is considered as one of the best choice to 
prevent the diseases caused by EV71. 
The VP1 protein which is the most immunogenic capsid protein of EV71, can be 
used in the development of subunit EV71 vaccines. The complete VP1 protein of 
EV71 was truncated into six regions and fused to the full length nucleocapsid 
protein (NPfl) and truncated NP (NPt; which lacks 20% amino acids from its C- 
terminal end). Western blot analysis using rabbit anti-VP1 serum showed that the 
N-terminal region of the VP1 protein contained a major antigenic region. Of all 
the recombinant NP proteins, the ones carrying truncated VP1 protein, VP11-100 
were efficiently expressed in Escherichia coli system. Electron microscopic 
analysis of the purified NPt-VPl-loo revealed that this protein predominantly self- 
assembled into intact ring-like structure whereas NPfl-VPl-loo showed disrupted 
ring-like formations. Rabbits immunized with these purified recombinant proteins 
exhibited a strong immune response against the complete VP1 protein. The 
antisera of these recombinant proteins also reacted positively with the authentic 
EV71 when analyzed by an immunoflourescence assay thus suggesting their 
potential as subunit vaccine candidates against EV71 infections and also as 
immunological reagents for the detection of anti-EV71 antibodies in serum 
samples. 
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Enterovirus 71 (EV71) manusia merupakan sejenis virus manusia yang penting 
berasal dari genus Enterovirus dan famili Picornaviridae. Beberapa letusan 
penyakit yang disebabkan oleh EV71 telah dikaitkan dengan manifestasi 
penyakit saraf pusat di antaranya ialah penyakit tangan, kaki dan mulut (HFMD). 
Sehingga kini, tiada ubat yang berkesan untuk merawat jangkitan yang 
berkaitan. Oleh itu, perkembangan vaksin yang berkesan dianggap sebagai 
salah satu langkah yang terbaik dalam pencegahan penyakit-penyakit yang 
disebabkan oleh EV71. 
VP1 adalah protein EV71 yang paling immunogenik yang boleh digunakan dalam 
perkembangan vaksin subunit bagi EV71. Protein VPI yang lengkap telah 
dipendekkan kepada enam bahagian dan digabungkan kepada protein 
nukleokapsid yang lengkap (NPfl) dan protein nukleokapsid protein yang telah 
dipendekkan (NPt) dari virus penyakit sampar ayam (NDV). Analisis pemblotan 
~ERPUGTW SULTAN AWBL SMM) 
Western dengan menggunakan serum arnab anti-VP1 menunjukkan bahawa 
bahagian terminal-N protein VP1 mengandungi satu bahagian antigenik yang 
utama. Daripada kesemua protein-protein rekombinan NP, yang membawa 
protein VP1 , VPll-loo merupakan protein yang diekspreskan dengan paling 
berkesan dalam sistem Escherichia coli. Analisis mikroskopik elektron ke atas 
NPt-VPl-loo menunjukkan bahawa protein in membentuk struktur gegelang yang 
sempurna manakala NPfl-VPl-loo membentuk struktur gegelang yang pecah. 
Arnab-arnab yang diimunisasikan dengan protein-protein rekombinan ini juga 
telah menunjukkan tindak balas imun yang kuat terhadap protein VP1 yang 
lengkap. Antisera protein-protein rekombinan ini juga telah bergerak balas 
secara positif dengan EV71 yang tulen apabila dianalisis dengan asai 
imunofloresen lalu mengesyorkan potensi mereka sebagai d o n  vaksin subunit 
terhadap penyakit-penyakit EV71 dan juga sebagai reagen imunologik dalam 
pengesanan antibodi-antibodi anti-EV71 dalam sampel-sampel serum. 
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CHAPTER 1 
INTRODUCTION 
Human enterovirus 71 (EV71) belongs to the Picornaviridae family and has been 
noted as one of the causative agents of hand, foot and mouth disease 
(Chumakov et a/., 1979; Nagy et a/., 1982; Samuda et a/., 1987). The virus 
enters the host orally via consumption of feacal-contaminated food or water. To 
date, there is no effective drug treatment or vaccine available for EV71 infections 
(Shih et a/., 2000; Racaniello, 2001 ; McMinn, 2002). Many clinical and virological 
similarities between poliovirus and EV71 strongly suggest that the vaccine 
strategies used against poliovirus can also be adopted to control EV71 infections. 
As an example, the inactivated poliovirus vaccine (IPV) developed by Jonas Salk 
was highly effective in reducing the incidence rates of poliomyelitis in 1940s and 
1950s (Hull & Aylward, 2001). The same concept was applied to develop an 
inactivated EV71 vaccine to the Bulgarian epidemic in 1975 but no efficacy data 
has been obtained (Chumakov et a/., 1979). The potential of having virulent 
revertant virus of live attenuated vaccines (Lin et a/., 2002) has made protein- 
based subunit EV71 vaccine a more favorable choice for vaccine development. 
Subunit vaccines are much safer than the inactivated and attenuated vaccines as 
they cause fewer adverse effects. The isolated subunit protein in a proper 
conformation can possess neutralizing epitopes. In this regard, two subunit 
vaccines were developed based on the immunodominant capsid protein of EV71, 
VP1 (Wu et al., 2002). The DNA-based vaccine and recombinant protein vaccine 
were administered to elicit immune response and to protect susceptible newborn 
mice against lethal EV71 challenge. Both types of vaccines produced similar 
levels of neutralizing antibodies in the vaccinated dams. With a challenge dose of 
230 LD50 per mouse, mice born to dams immunized with the recombinant VPI 
protein and DNA vaccine showed 80% survival and 40% survival rates 
respectively. These findings strongly suggest the potential use of VP1 protein of 
EV71 for the development of effective subunit EV71 vaccines. 
Protein carriers have been extensively studied in the development of subunit 
vaccines. The use of an appropriate carrier can increase the overall yield, the 
solubility level as well as the immunogenicity of the recombinant proteins 
(LaVallie & McCoy, 1995). In relation to this, the nucleocapsid protein (NP) of 
Newcastle disease virus (NDV) has been demonstrated to be a potential 
molecular carrier of antigenic proteins (Kho et a/., 2001; Rabu et a/., 2002). The 
chimeric NP proteins were expressed as highly soluble and stable proteins in the 
E. coli system. In addition, due to the NP protein, the chimeric proteins were also 
easily purified by sucrose gradient centrifugation and they readily self-assembled 
into ring-like particles when viewed under an electron microscope. Furthermore, 
specific pathogen free (SPF) chickens immunized with these chimeric particles 
elicited an immune response against NDV, suggesting the possible use of NP as 
a carrier for immunogens in the development of subunit vaccines and 
immunological reagents (Rabu et a/., 2002). 
In view of this, the objectives of the whole study are first, to construct 
recombinant NP proteins harbouring the polypeptides of VP1 of EV71. Second, 
to select recombinant NP proteins that are abundantly expressed in soluble form. 
Third, to evaluate the potential of these recombinant NP proteins in inducing 
immune response in animals and lastly, to determine the viral neutralization 
properties of the antibodies raised against these recombinant proteins. 
In order to achieve these objectives, the study begun with the cloning of the 
truncated VP1 fragments encoding several antigenic polypeptides into an 
expression vector harbouring the NP coding gene. The recombinant proteins 
were expressed in E. coli cells whereby highly expressed and soluble 
recombinant proteins were subjected to purification by sucrose gradient 
ultracentrifugation. Electron microscopic analysis was done to observe the 
structure of these recombinant proteins. The purified recombinant proteins were 
then used to immunize rabbits and its antigenicity and the immunogenicity were 
examined by various methods. 
CHAPTER 2 
LITERATURE REVIEW 
2.1 The EV71 Protein: VP1 
2.1.1 The History 
Human enterovirus 71 (EV71) was first identified in 1969 in California, following 
its isolation from an infant suffering from encephalitis (Schmidt et a/., 1974). The 
first isolation of EV71 outside of USA was reported in Melbourne, Australia, 
during an epidemic of aseptic meningitis between 1972 and 1973 (Kennett et a/., 
1974). In 1975, this virus gained global attention after an outbreak in Bulgaria 
that resulted in 705 cases of poliomyelitis-like disease and 44 deaths, with most 
of these cases involving children under the age of five (Chumakov et a/., 1979). 
The very first association of EV71 with hand, foot and mouth disease (HFMD), 
was reported only after small epidemics in both Sweden (Blomberg et a/., 1974) 
and Japan (Gobara et a/., 1977; Hagiwara et a/., 1978) in 1973. Since then, 
several large epidemics and high-level endemic circulation have been reported in 
the Asia-Pacific region. The first such epidemic in Malaysia occurred in Sarawak 
in 1997 (Cardosa et a/., 1999), followed by smaller outbreaks in Japan (Komatsu 
et a/., 1999), Peninsular Malaysia (Lum et a/., 1998) and Singapore in 1998 
(Singh et a/., 2000). These outbreaks were associated with numerous cases of 
HFMD, herpangina, aseptic meningitis, acute flaccid paralysis (AFP), cerebellar 
ataxia and even the fatal neurogenic pulmonary oedema (Chang et a/., 1999) 
associated with severe brainstem encephalitis (Chang et a/., 1998; Huang eta/., 
The largest EV71 epidemic outbreak took place in Taiwan in 1998, with more 
than 100,000 cases of HFMD being reported (Ho et a/., 1999). Subsequently, 
another large outbreak was also reported in Perth, Australia in 1999 (McMinn et 
a/., 2001). Virological studies were done and both EV71 and Coxsackievirus A16 
(CA16) were isloated from these outbreaks but the former was the predominant 
virus. EV71 continues to circulate in the Asia-Pacific region and in February 
2003, the virus was again reported in Sarawak, Malaysia. Most of the cases 
reported were uncomplicated HFMD but a small number did have neurologic 
disease (Cardosa et a/., 2003). 
2.1.2 Virus Classification 
Enterovirus 71 belongs to the family Picornaviridae, genus Enterovirus and the 
species Human enterovirus A. Initially, the original 64 human enterovirus 
serotypes were grouped into polioviruses (PV), coxsackieviruses A (CA), 
coxsackieviruses B (CB) and echoviruses (EV) 68 to 71. The major characteristic 
